INS and type 1 diabetes mellitus: Therefore, it was hypothesized that alefacept might prolong the preservation of endogenous insulin secretion by the remaining beta-cells in new-onset patients by changes in effector T cells, The Immune Tolerance Network Type 1 Diabetes with Alefacept (TIDAL) study.